The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.

The ASPIRE trial design was altered due to pushback from patient advocates who felt it was unethical to randomize metachronous low-volume disease patients to a chemotherapy arm. This led to the exclusion of that subgroup, demonstrating how advocate consensus can override a purely biology-based trial design in favor of perceived patient benefit.

In the ASCENT-07 trial, investigators may have prematurely switched patients from the standard chemotherapy arm to superior, commercially available ADCs at the first hint of progression. This real-world practice can mask an experimental drug's true benefit on progression-free survival.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

The common practice of switching from one ARPI to another upon disease progression is now considered ineffective for most patients. With the advent of proven alternatives like chemotherapy and lutetium, using an "ARPI switch" as the sole control arm in clinical trials is no longer ethically or scientifically sound.

The expected rapid approval of the highly effective RAS inhibitor daraxonrasib poses a dual crisis. It creates an urgent need for equitable patient access globally while simultaneously making future randomized trials against standard chemotherapy nearly impossible to recruit, as patients will be unwilling to join the control arm.

Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.

The trial's principal investigator initially designed a control arm of prostatectomy alone. However, to maintain blinding and prevent patients from dropping out over a multi-year follow-up, a compromise was made to use ADT plus placebo, highlighting the pragmatic trade-offs required in large-scale clinical trials.

The lack of randomized trials comparing new bladder cancer drugs to the standard of care, gemcitabine-docetaxel, isn't just about cost. There's an underlying fear within pharmaceutical companies that their expensive new agents may not prove superior to the highly effective and inexpensive 'gemdose,' stalling meaningful progress.